INDICATION
LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).
IMPORTANT SAFETY INFORMATION
Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.
Please click
here
for LEQVIO full Prescribing Information.
INDICATION
LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of
adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce
low-density lipoprotein cholesterol (LDL-C).
IMPORTANT SAFETY INFORMATION
Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo)
were injection site reaction, arthralgia, and bronchitis.
Please click
here
for LEQVIO full Prescribing Information.